Skip to main content
. Author manuscript; available in PMC: 2015 Dec 5.
Published in final edited form as: Cell Rep. 2015 Nov 25;13(9):1789–1799. doi: 10.1016/j.celrep.2015.10.068

Figure 4. A3G position 125 interact with Vif amino acids 19 and 22.

Figure 4

(A) Four patient-derived Vifs that counteract A3G-125R and do not encode an arginine or lysine at both position 19 and 22 were mutated to 19R and 22K.

(B) The four patient Vifs and their respective mutants were tested in single cycle infectivity assays in the presence of A3G-125R (left panel) and WT A3G (right panel) and 293T cell lysates were analyzed by western blot.

(C) LAI Vif, which encodes 19R and 22K and does not counteract A3G-125R, was mutated at positions 19 and 22 with the indicated residues. Antiviral activity of these Vif mutants was tested in the presence of A3G-125R (D, left panel) or WT A3G (D, right panel). 293T cell lysates were analyzed by western blot.

(E) Immuno-precipitations were performed with WT LAI Vif and its 19 and 22 mutants and WT A3G or A3G-125R. Proteins were analyzed by western blot.

(F) Combined, our data show that Vif-19+22 interact with A3G-125. See also Figure S2.